During a virtual event, Neil M. Iyengar, MD, and participants discussed how approvals for trastuzumab deruxtecan before and after surgery complicate sequencing for patients with HER2-positive early breast cancer.
|Videos|July 15, 2020
The Evolving Role of Tucatinib in HER2-Positive Metastatic Breast Cancer
Author(s)Sara A. Hurvitz, MD
A key opinion leader discusses how the role tucatinib is evolving in the management of HER2-positive metastatic breast cancer.
Advertisement
Advertisement
Related to this article
A phase 2 trial is planned for an allogeneic CAR T-cell product in patients with lung or breast cancer with brain metastases.
The phase 2 NRG-BR002 failed to improve outcomes with targeted radiotherapy to oligometastases; the phase 3 portion will not proceed.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Selpercatinib Shows Durable Responses in Pediatric Solid Tumors
2
Dostarlimab Receives FDA Approval for MSI-H/dMMR Locally Advanced Rectal Cancer
3
Male Sex, Age, and Tumor Genetics Linked to Thyroid Cancer Mortality
4
2026 AACR Report Highlights Advances and New Directions in Cancer Treatment
5